Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

INTUITIVE SURGICAL INC Director's Dealing 2024

Jan 29, 2024

29809_dirs_2024-01-29_e296a132-e1a6-4f4e-8c93-3875fa95c177.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INTUITIVE SURGICAL INC (ISRG)
CIK: 0001035267
Period of Report: 2024-01-26

Reporting Person: LEVY ALAN J (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-01-26 Common Stock M 72 $154.2367 Acquired 25391 Direct
2024-01-26 Common Stock S 72 $370.2024 Disposed 25319 Direct
2024-01-26 Common Stock M 1928 $90.4944 Acquired 27247 Direct
2024-01-26 Common Stock S 1928 $370.2024 Disposed 25319 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-01-26 Non-Qualified Stock Option (right to buy) $90.4944 M 1928 Disposed 2027-04-20 Common Stock (1928) Direct
2024-01-26 Non-Qualified Stock Option (right to buy) $154.2367 M 72 Disposed 2028-04-19 Common Stock (72) Direct

Footnotes

F1: These shares were sold in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on May 8, 2024.

F2: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $368.90 to $371.65 as follows: 900 shares sold at $368.90 to $369.78; 600 shares sold at $370.04 to $370.71; and 500 shares sold at $371.60 to $371.65. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company.